Document is current
Any future updates will be listed below
-
Authors
Elvebakken, Hege https://orcid.org/0000-0001-7458-4836
Venizelos, Andreas
Perren, Aurel https://orcid.org/0000-0002-6819-6092
Couvelard, Anne
Lothe, Inger Marie B.
Hjortland, Geir O.
Myklebust, Tor Å. https://orcid.org/0000-0003-4645-1635
Svensson, Johanna
Garresori, Herish
Kersten, Christian
Hofsli, Eva
Detlefsen, Sönke
Vestermark, Lene W.
Knappskog, Stian https://orcid.org/0000-0002-4153-1655
Sorbye, Halfdan
- License Information
-
More Information
Article History
Received: 20 December 2023
Revised: 7 June 2024
Accepted: 17 June 2024
First Online: 22 June 2024
Competing interests
: HG: Honoraria from Ipsen, Amgen, Pfizer, Bristol Meyer Squibb and Astra Zeneca, SK: Research support from AstraZeneca, Pfizer and Illumina and honoraria from AstraZeneca, Pfizer, Pierre- Fabre, Novartis, Sobi, Amgen, Sanofi Aventis and Roche, HS: Consultant/advisory board: Hutchison, Bayer, ITM, Advanced Accelerator. Lecture honoraria: Novartis, Ipsen, Bayer, SAM Nordic, Pierre Fabre. The other authors have no disclosures.
: The study was conducted according to the Declaration of Helsinki, and approved by ethics committees in Norway (REK vest 2012/940), Sweden (REC Uppsala Dnr 2012/285) and Denmark (Region Hovedstaden H-4-2012-108). All patients signed written informed consent.
